About Ambrose Healthcare
Ambrose Healthcare is a UK-headquartered, rare disease-focused biopharmaceutical company.
Driven to do more
The Ambrose team is no stranger to the rare disease space. We have witnessed physicians struggle to treat patients, drugs narrowly miss trial endpoints because patients weren’t involved in setting meaningful endpoints, and watched promising drugs in the industry stall. Many of our team have lived experience of a rare disease, personally or through a close family member. It is why Ambrose exists.
Understanding the market opportunity and the patient needs, we are building a new business with a double-bottom line: balancing financial performance and social responsibility.
Growing ahead of plan
Since our launch in early 2023, we have assembled an expert team with deep roots in pharmaceuticals and rare diseases, acquired drug candidates ahead of schedule and appointed an expert medical advisory board to support our clinical programmes. In addition, we established a global network of rare disease experts and organisations to collaborate with on our Early Access Programs, clinical trials, manufacturing, IP development and regulatory approvals. In October 2026 we acquired AM-Pharma, adding ilofotase alfa for hypophosphatasia (HPP) as our third clinical-stage programme and giving us our first base in Europe, in Utrecht, the Netherlands.
An experienced team
Together, the members of the Ambrose team have more than 200 years of combined experience in pharmaceuticals. They have the expertise to bring new treatments to market and a curiosity for doing things differently.
We operate a model of 'entrepreneurship without borders' - operating with diversity across geography, subject matter expertise, gender and age. As we develop our team, we consistently evaluate if we are incorporating a sufficient range of perspectives.